首页> 美国卫生研究院文献>Chemical Science >Toward redesigning the PEG surface of nanocarriers for tumor targeting: impact of inner functionalities on size charge multivalent binding and biodistribution
【2h】

Toward redesigning the PEG surface of nanocarriers for tumor targeting: impact of inner functionalities on size charge multivalent binding and biodistribution

机译:旨在重新设计用于肿瘤靶向的纳米载体的PEG表面:内部功能对尺寸电荷多价结合和生物分布的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Achieving accurate and efficacious tumor targeting with minimal off-target effects is of paramount importance in designing diagnostic and therapeutic agents for cancer. In this respect, nanocarriers have gained enormous popularity because of their attainable multifunctional features, as well as tumor-targeting potential by extravasation. However, once administered into the bloodstream, nanocarriers face various in vivo obstacles that may significantly impair their performance needed for clinical translation. Herein, we demonstrate a strategy to enhance tumor-targeting efficiency by embedding functionalities in the interior region of partially PEGylated nanocarriers (ca. 10 nm in diameter), intended for active or passive targeting. The cooperative impact of these topologically inner functional groups (IFGs) was marked: enhancements of >100-fold in IC50 in vitro (e.g., a high-avidity ligand with cationic IFGs) and >2-fold in tumor accumulation at 2 h post-injection in vivo (e.g., a high-avidity ligand with anionic IFGs), both against the fully PEGylated counterpart. Analogous to allosteric modulators, properly employed IFGs may substantially improve the process of effectively directing nanocarriers to tumors, which is otherwise solely dependent on avidity or extravasation.
机译:在设计出用于癌症的诊断和治疗剂时,以最小的脱靶效应实现准确有效的肿瘤靶向至关重要。在这方面,纳米载体由于其可获得的多功能特征以及通过外渗的靶向肿瘤的潜力而获得了极大的普及。然而,一旦被送入血液,纳米载体将面临各种体内障碍,这些障碍可能会大大削弱其临床翻译所需的性能。在本文中,我们展示了一种通过在部分PEG化纳米载体(直径约10 nm)的内部区域嵌入功能性(旨在进行主动或被动靶向)来增强肿瘤靶向效率的策略。这些拓扑内部功能基团(IFG)的协同作用是明显的:体外IC50增强> 100倍(例如,具有阳离子IFG的高亲和力配体),并且在2 h后肿瘤积累中> 2倍。均针对完全PEG化的对应物进行体内注射(例如,具有阴离子IFG的高亲和力配体)。类似于变构调节剂,正确使用的IFG可以显着改善将纳米载体有效引导至肿瘤的过程,否则它仅依赖于亲和力或外渗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号